ACT-Accelerator – Plan, Investment Case, & Advocacy Campaign

Civil Society & Community Organization Briefing

29 September 2020
Goals

- **Sharing the ACT-Accelerator Story:** from start-up to scale-up

- **Understanding the Investment Case:** & financing requirements

- **Joining the ACT-A Advocacy Campaign:** financing ACT-A

- **Supporting CSOs:** how can we take advocacy forward together?
The ACT-Accelerator Plan & Investment Case
Released 25 September 2020

Status Report & Plan provides an overview of ACT-Accelerator’s goal, approach, achievements to date & near-term priorities.

Investment Case provides an economic rationale for investing in ACT-A as a global, integrated, ‘end-to-end’ solution.

Developed collectively by Partners in consultation with the Facilitation Council
**ACT-A goal:** accelerated global access to tools that rapidly reduce risk of severe disease & end acute phase of pandemic

- **Diagnostics**
  - 500 million tests by mid-2021

- **Asymptomatic & mild disease**
  - 80%

- **Severe disease**
  - 20%

- **Hospital / ICU overload**

- **Extreme physical distancing**

- **Health, social & economic disruption**

- **Vaccines**
  - 2 billion doses by the end of 2021

- **Therapeutics**
  - 245 million courses by mid-2021

- **Access & Allocation**
  - to ensure global equitable access to these tools

**Health systems**
- to provide PPE, supply O2, & support delivery of safe essential services

**Diagnostics**
- to enable rapid case isolation & treatment

**Vaccines**
- to protect from disease, death & transmission

**Therapeutics**
- to prevent & provide treatment for disease

**Diagnostics**
- to provide PPE, supply O2, & support delivery of safe essential services
ACT-A’s critical path uses accelerated & parallel workstreams to rapidly achieve its goal

Key achievements
- 500+ actionable trials followed across products
- 100s of trials deep dived across geographies and sub-populations
- Regulatory approval and licensure of safe and efficacious tools

Major milestones
- In progress

In progress
- Key achievements
- Major milestones

End the acute phase of the pandemic

R&D
- 500+ actionable trials followed across products
- 100s of trials deep dived across geographies and sub-populations
- Regulatory approval and licensure of safe and efficacious tools

Manufacturing
- Procure / reserve scarce resources
- Manufacture products at risk
- Align on portfolio of candidates across products
- Reach global scale by expanding and allocating capacity

Procurement
- Perform rapid response procurement
- Set up advance commitments to shape market & ensure access for all countries
- Define allocation mechanisms based on framework
- Strike early-access deals

Delivery
- Define fair allocation framework to achieve equitable access
- Issue policies to inform usage
- Prepare for LIC / LMIC country delivery & infrastructure
- Launch and support deployment programs
- Sustain monitoring & learning
ACT-A is a bold structure, driving unprecedented collaboration

Deep engagement of Principals, integrated workplans & budgets, working with the entire development system

- Governments
- Civil Society
- Industry
ACT-A is the most effective investment to address COVID-19 & its consequences

<table>
<thead>
<tr>
<th>Comprehensive public health tool box</th>
<th>ACT-A is the only mechanism with Vaccines, Therapeutics, Diagnostics, PPE and O2, the full spectrum of products needed to beat the pandemic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reduces R&amp;D risks</td>
<td>ACT-A has the largest and most diverse R&amp;D portfolio in the world</td>
</tr>
<tr>
<td>Mitigates operational risks</td>
<td>ACT-A co-conveners are the experts in implementing global public health</td>
</tr>
<tr>
<td>Unique global reach</td>
<td>ACT-A, by design, is the only mechanism that looks after all the people at the same time</td>
</tr>
</tbody>
</table>
Some key landmarks from the start-up phase

- **Diagnostics**: new Ag RDTs, with EULs & volume/price guarantees
- **Vaccines**: COVAX Facility in business (167 countries & growing)
- **Allocation**: WHO Framework is the emerging standard
- **Therapeutics**: Dexamethasone now in rollout

*Concrete outcomes of the ACT-Accelerator Collaboration*
### Immediate *priorities for Oct – Dec 2020*

<table>
<thead>
<tr>
<th>R&amp;D</th>
<th>Manufacturing</th>
<th>Procurement</th>
<th>Delivery</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Vaccines</strong></td>
<td>Add 1-5 candidates to portfolio based on imminent readouts</td>
<td>Negotiate new deals with manufacturers based on imminent Phase II/II results</td>
<td>Step up country preparedness efforts to deploy as soon as possible</td>
</tr>
<tr>
<td><strong>Therapeutics</strong></td>
<td>Evaluate new monoclonal antibodies and antivirals</td>
<td>Select molecules for 1st wave of manufacturing capacity reservations</td>
<td>Launch 3-5 further market interventions for repurposed medicines</td>
</tr>
<tr>
<td><strong>Diagnostics</strong></td>
<td>Accelerate evaluation of novel diagnostics</td>
<td>Rollout 10s of millions of antigen-detecting RDTs</td>
<td>Pre-empt deployment needs for antigen-detecting RDTs</td>
</tr>
</tbody>
</table>

*Cross-cutting priorities detailed in Plan*
BUT…ACT-A needs 2 major step changes in this crucial period

**Step change in financing to scale up for impact, $ B rounded**

<table>
<thead>
<tr>
<th>Start-up (pledges)</th>
<th>Scale up (needs)</th>
<th>Total budget</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.3</td>
<td>2.0</td>
<td>2.7</td>
</tr>
<tr>
<td>0.1</td>
<td>2.0</td>
<td>2.1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Vx</th>
<th>Tx</th>
<th>Dx</th>
<th>HSC</th>
</tr>
</thead>
<tbody>
<tr>
<td>35</td>
<td>14</td>
<td>7</td>
<td>9</td>
</tr>
<tr>
<td>38</td>
<td>16</td>
<td>7</td>
<td>9</td>
</tr>
</tbody>
</table>

**New level of coordination for roll out of scarce vaccines** Vaccine doses secured¹, M doses by 2021

- **Domestic (US, UK, IN, BR)²**: 1,000+
- **Regional (EC³)**: 1,250
- **Global (COVAX)**: 2,000

ACT-A ambition
Understanding the ACT-A Investment Case & Financing Needs
The economic argument | unprecedented domestic stimulus has helped hedge the crisis but only in some sectors & countries

$US 10 trillion in stimulus unlocked by G20 countries to support businesses & economies

Size of stimulus package – in $B

Economic support is already showing mixed outlook

Financial indices – 100=1 Jan-20, as of 31 August 2020

EU unemployment rate – in % population¹

¹ Source: OECD Data
Sectors that depend heavily on international trade & mobility will not recover with existing government stimulus

<table>
<thead>
<tr>
<th>Economic sector</th>
<th>High-income countries (HIC)</th>
<th>Low-income countries (LIC)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dependent on mobility &amp; global trade</td>
<td>&gt; $8 trillion loss in revenues(^2)</td>
<td>&gt; $4 trillion loss in revenues(^3)</td>
</tr>
<tr>
<td>Dependent on domestic demand</td>
<td>$10 trillion loss in GDP(^1)</td>
<td>&gt; $6 trillion loss in GDP(^4)</td>
</tr>
</tbody>
</table>

Rapidly reducing severe COVID-19 disease in LIC/LMICs would save lives and fully restore international mobility & trade and long term growth

Equitable access to COVID-19 tools will allow LIC/LMIC domestic economies to recover...

...restoring international mobility & trade and delivering short term value and long term growth to HICs.¹

¹ Emerging markets are contributing to 74% of 2020 GDP growth and 30% of international trade; source: WTO, IMF
**Financing Requirements & Economic Rationale:** the $US35 Bn is paid back in 36 hours, once int’l mobility & trade is restored

<table>
<thead>
<tr>
<th></th>
<th>Total Ask</th>
<th>Proportion funded</th>
<th>Immediate gap(^1)</th>
<th>Funding gap(^2)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Therapeutics</strong></td>
<td>$7B</td>
<td>$0.3B</td>
<td>$4B</td>
<td>$7B</td>
</tr>
<tr>
<td><strong>Vaccines</strong></td>
<td>$16B</td>
<td>$2B</td>
<td>$7B</td>
<td>$14B</td>
</tr>
<tr>
<td><strong>Health Systems</strong></td>
<td>$9B</td>
<td>$0.1B</td>
<td>$2B(^3)</td>
<td>$9B</td>
</tr>
<tr>
<td><strong>Diagnostics</strong></td>
<td>$6B</td>
<td>$0.3B</td>
<td>$2B</td>
<td>$6B</td>
</tr>
</tbody>
</table>

**Funding gap\(^1\)**

- Over 1 month: $7B
- Over 36 hours: $3B
- Over 18 months: $12T
- Total: $35B

**Revenue losses of Travel and Tourism alone over 2020-2021**

1. Additional critical funding required by end of 2020 to meet ACT-Accelerator targets (excl. proportion already funded); 2. As of 7 September 2020; 3. Assuming 25% of total ask in 2020
Evolving arc of the ACT-Accelerator Advocacy Campaign

1. Prepare: Build & share strong rationale
   - Move toward political consensus for coordinated global response
   - Awareness of ACT-A raised among key Finance, Trade, & Health influencers

2. Ignite: Secure significant new pledges
   - World leaders catalyze a step-change in support for ACT-A
   - Financiers reinforce economic case & start to respond

3. Harvest: Close ACT-A financing gap
   - Commitment grows & funding gap narrows

GOAL: Close ACT-A $35B financing gap by March 2021

- 10 Sep: ACT-A Facilitation Council launched
- 17 Sep: Joint meeting of G20 Finance & Health Ministers
- 22 Sep: G20 Trade Ministers meeting
- 14 Oct: G20 Finance & Central Bank Ministers meeting
- 25-27 Oct: World Health Summit Germany
- 12-18 Oct: IMF & World Bank annual meetings
- 21-22 Nov: G20 Leader’s summit
- 30 Sep: UNGA high-level side event on ACT-A
- 10-11 Nov: Paris Peace Forum
- 21-22 Nov: G20 Leader’s summit
1st Council: Final Outcome Statement & Next Steps

‘We will

• provide sustained political leadership...

• advocate for the ACT-A Investment Case...

• honour our shared commitment to leave no-one behind’

Next steps: planning meetings with Co-Chairs on week basis

Available at: https://www.who.int/news-room/detail/10-09-2020-statement-from-the-first-act-accelerator-facilitation-council-meeting
ACT-A at UNGA:
30 September 2020

Registration open at:
https://access-for-all.world-television.com/register
Advocacy Campaign: Financing the ACT-Accelerator
Global framing of the ACT-Accelerator Ask:
Beyond ODA to 1% of Fiscal Stimulus*

- The lack of an adequately financed global exit strategy is an **existential threat to the economic and health security of all** nations and citizens.

- **Only by tackling the causes of the pandemic, globally,** will economic vitality be restored at home & catastrophe in poorest countries be averted.

- **ACT-A is the only comprehensive investment approach** that can address the root cause of the COVID-19 crisis & accelerate the end of the pandemic.

- **G20/OECD countries are called upon to contribute 1% of domestic stimulus spending, or the equivalent amount, to the global COVID-19 response,** with the first funds going to fully funding the ACT-Accelerator.

*To be adapted in individual markets depending on context*
**Unpacking the numbers:** how might the $38 billion ACT-Accelerator budget be funded?

**Underpinning assumptions**

- ~10% of ACT-A budget could be funded by private sector & EC
- remaining funding needs covered primarily by G20/OECD
- a substantive proportion could be covered by concessional loans / domestic resources (TBD)
ANALYTIC: 1% fiscal stimulus for global response priority is 0.34% for a fully-funded ACT-A

12 countries represent up to 90% of the G20 “ask”

This analytic is illustrative.

NEXT STEP: adapting & developing individual markets/contexts ‘asks’

Source: IMF, World Bank; BCG analysis
Securing a fully-funded ACT-Accelerator will require extraordinary action by world leaders

- ACT-A is an integral part of economic stimulus & must be financed accordingly

- There is not $35 Bn of funding (in next 6 months!) in ODA budgets

- Making ACT-A funding available requires an all-of-government approach (Head of Govt, Health, Finance, Treasury, Development, MoFA, Trade...)

- Ensuring ACT-A is fully financed is in countries’ enlightened self-interest

- Deep engagement by CSOs & Community Organizations will be critical
Social Media pack ACT-Accelerator

Social media toolkit link

Social Media Toolkit for ACT-Accelerator

#ACTTogether
#COVID19
ACT Accelerator is a proven, up-and-running, COVID-19 exit strategy for the world & is already delivering returns.

ACT-A is the only mechanism explicitly designed to achieve:

- a simultaneous end to the pandemic everywhere,
- with a concomitant return to health, and
- a faster and more sustained return to global mobility, trade & economic activity

We are calling on leaders around the world to ACT NOW to change the course of the pandemic.
How can CSOs take forward ACT-A advocacy?